Companies · Biotech / Pharma
BOULDER · Biotech / Pharma · refined from filed group “Other”
Diligence memoA one-page analyst read on Pharmaca Integrative Pharmacy Inc — recommendation, valuation, rhythm, risks.→Pharmaca Integrative Pharmacy Inc looks fair against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Pharmaca Integrative Pharmacy Inc is one of 227 Biotech / Pharma companies tracked from BOULDER. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.
Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.
Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 67% of sector peers (real $). Modeled value above 81% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #2 of 5.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Oncoheroes Biosciences Inc. | Series A | $8.9M | $296.5M | 1.36× |
| Pharmaca Integrative Pharmacy Inc this company | Series A | $13.6M | $234.5M | 1.08× |
| PharmacoPhotonics, Inc. | Series A | $16.6M | $217.9M | 1.00× |
| Key Biologics Holdings, LLC | Series A | $10.6M | $167.5M | 0.77× |
| Swift Biosciences, Inc. | Series A | $31.5M | $134.0M | 0.61× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series A | $6.1M | 2009-03-09 | $27.9M | $205.7M | 85% |
| Series A | $6.6M | 2009-07-31 | $29.8M | $219.6M | 85% |
| Series A | $7.0M | 2017-01-31 | $31.8M | $234.5M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Corey Mulloy | — | 4 other | 2009-07 |
| Richard Willis | — | 4 other | 2017-01 |
| William Rosenzweig | — | 4 other | 2009-03 |
| Greg Scott | — | 2 other | 2009-03 |
| Joel D. Liffmann | — | 2 other | 2009-07 |
| Thomas Stemberg | — | 2 other | 2009-03 |
| Alan Kessock | — | 1 other | 2009-07 |
| David Maher | — | 1 other | 2009-03 |
| Martin Hanaka | — | 1 other | 2017-01 |
| Peter Cornetta | — | 1 other | 2017-01 |
| Anya Hayden | — | — | 2017-01 |
| Barry Perzow | — | — | 2009-03 |
| Gregory D. Scott | — | — | 2009-07 |
| Janet Mathews | — | — | 2009-03 |
| Joel Liffmann | — | — | 2009-03 |
| Mark Panzer | — | — | 2009-03 |
| Michael Kruteck | — | — | 2017-01 |
Pharmaca Integrative Pharmacy Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Hollister Biosciences Inc. | Biotech / Pharma | Series A | $13.5M | $21.2M | same sector · same stage |
| Onyx Bio, Inc. | Biotech / Pharma | Series A | $13.3M | $19.6M | same sector · same stage |
| Ruby Bio, Inc. | Biotech / Pharma | Series A | $13.1M | $27.7M | same sector · same stage |
| Generian Pharmaceuticals, Inc. | Biotech / Pharma | Series A | $13.0M | $435.2M | same sector · same stage |
| Accipiter Biosciences Inc. | Biotech / Pharma | Series A | $14.2M | $75.0M | same sector · same stage |
| Sistema.bio, Inc. | Biotech / Pharma | Series A | $14.2M | $21.5M | same sector · same stage |
| Araceli Biosciences Inc. | Biotech / Pharma | Series A | $14.5M | $50.4M | same sector · same stage |
| GID BIO, Inc. | Biotech / Pharma | Series A | $12.7M | $90.0M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| PharmaCann Inc. | Biotech / Pharma | Series D+ | $413.5M | 87% |
| PharmaCCX, Inc. | Biotech / Pharma | Series A | $45.1M | 85% |
| Intera Oncology Inc. | Pharma | Seed | $9.0M | 84% |
| Continuum Biosciences, Inc. | Biotech / Pharma | Pre-Seed | $25.6M | 83% |
| Puna Bio Corp | Biotech / Pharma | Series B | $108.6M | 83% |
| Me Biosciences, Inc. | Biotech / Pharma | Pre-Seed | $25.6M | 83% |
| INIA Biosciences, Inc. | Biotech / Pharma | Pre-Seed | $1.3M | 83% |
| Circe Biosciences Inc. | Biotech / Pharma | Seed | $33.4M | 83% |
See where Pharmaca Integrative Pharmacy Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Pharmaca Integrative Pharmacy Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.